Previous 10 | Next 10 |
home / stock / pfe / pfe articles
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023. ...
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) ...
The stock market witnessed a notable surge today, with the Dow Jones rising 0.43% to 37,248.35 and the S&P 500 gaining 0.26% to 4,719.55. The N...
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's pr...
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE), lowering the price target to $3...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Major U.S. indices were in the green on Wednesday with the Dow Jones rising 1.4% to 37,090.24, the S&P 500 gaining 1.37% to 4,707.09 and the te...
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 06:28:00 ET Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess ...
2024-07-01 10:48:00 ET It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago....
Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer’s Board. Mr. Taraporevala served as Presid...